SequelSEC

BIOLIFE SOLUTIONS INC BLFS

Electromedical & Electrotherapeutic Apparatus · CIK 0000834365 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$28.47M
Fiscal year ended 2026-06-30
Operating income
$1.70M
Fiscal year ended 2026-06-30
Free cash flow
$5.30M
Fiscal year ended 2026-06-30

BIOLIFE SOLUTIONS INC (BLFS) reported revenue of $28.47M and net income of $45.10M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BIOLIFE SOLUTIONS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Electromedical & Electrotherapeutic Apparatus.

Income

BIOLIFE SOLUTIONS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$28.47M$27.50M$18.78M$28.07M$23.44M$22.05M$15.11M$21.39M$19.72M$18.43M
Cost of revenue$10.18M$10.00MUnavailableUnavailable$8.20M$7.25MUnavailableUnavailableUnavailableUnavailable
Gross profit$18.29M$17.50MUnavailableUnavailable$15.24M$14.80MUnavailableUnavailableUnavailableUnavailable
Operating income$1.70M$27.00K$1.35M-$89.00K-$16.13M-$499.00K$542.00K-$418.00K-$1.31M-$3.30M
Net income$45.10M$1.19M$11.07M$621.00K-$15.84M-$448.00K$12.46M-$1.70M-$20.72M-$10.22M
Research & development$2.96M$2.65M-$67.00K$2.71M$1.96M$1.44M-$1.25M$1.89M$2.03M$2.08M
Weighted-average diluted sharesshares 49.29Mshares 49.25MUnavailableshares 48.72Mshares 47.80Mshares 48.37MUnavailableshares 46.18Mshares 46.00Mshares 45.43M
Pretax income$2.75M$1.25M$3.36M$703.00K-$15.20M$285.00K$469.00K-$551.00K-$5.56M-$3.18M
Income tax expense-$42.35M$62.00K-$173.00K$82.00K$126.00K$14.00K$24.00K-$80.00K$1.00K$17.00K
Diluted EPS$0.91$0.02Unavailable$0.01$-0.33$0.00Unavailable$-0.04$-0.45$-0.22
Selling, general & administrative$13.48M$14.73M$12.54M$14.60M$13.81M$13.79M$13.15M$11.83M$11.80M$12.77M
General & administrative$10.69M$12.21M$10.55M$12.07M$11.23M$11.35M$11.59M$9.33M$9.32M$10.40M
Selling & marketing$2.78M$2.53M$1.99M$2.53M$2.58M$2.44M$1.57M$2.51M$2.48M$2.38M

Balance

BIOLIFE SOLUTIONS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$24.00M$22.82M$33.04M$29.48M$31.90M$66.94M$91.54M$23.98M$22.01M$29.69M
Total assets$447.49M$400.91M$405.88M$392.08M$387.24M$395.14M$399.49M$381.65M$374.98M$401.60M
Current assets$135.20M$133.22M$136.56M$126.57M$125.43M$131.13M$148.76M$89.38M$88.20M$111.70M
Total liabilities$27.49M$28.68M$34.00M$38.34M$40.08M$42.52M$50.58M$56.19M$53.53M$68.20M
Current liabilities$13.95M$18.25M$22.98M$27.15M$28.31M$27.72M$32.73M$32.17M$30.82M$38.66M
Total equity incl. NCI$420.00M$372.23M$371.89M$353.74M$347.16M$352.62M$348.91M$325.46M$321.44M$333.40M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$35.59M$32.83M$30.16M$27.82M$27.69M$27.57M$29.01M$32.18M$32.50M$43.41M
Accounts receivable$10.65M$13.06M$7.95M$10.84M$10.06M$9.17M$8.48M$17.92M$18.06M$18.57M
Goodwill$208.59M$208.59M$208.59M$212.30M$212.30M$212.30M$208.59M$224.74M$224.74M$224.74M
Long-term debt$0$2.50M$5.00M$0$0$2.50M$5.00M$7.82M$10.45M$15.68M
Accounts payable$2.48M$3.75M$1.49M$2.89M$3.21M$3.30M$3.36M$3.84M$4.21M$4.98M

Cash flow

BIOLIFE SOLUTIONS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow$6.35M-$491.00K$4.92M$6.10M$7.37M$1.73M$1.64M$4.80M$6.46M-$4.48M
Capital expenditures$1.04M$167.00KUnavailableUnavailable$1.74M$175.00KUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$1.58M-$1.83M$1.14M-$5.97M-$39.53M-$27.18M$73.64M-$1.68M-$13.44M-$221.00K
Financing cash flow-$3.59M-$7.90M-$2.50M-$2.56M-$2.88M-$2.99M-$4.09M-$1.04M-$704.00K-$952.00K
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$3.85M$4.81M$7.08M$5.90M$5.86M$4.15M$10.69M$5.33M$8.72M$6.18M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$411.00K$374.00K$261.00K$636.00K$674.00K$682.00K$937.00K$1.41M$1.45M$1.36M

Derived

BIOLIFE SOLUTIONS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow$5.30M-$658.00KUnavailableUnavailable$5.62M$1.55MUnavailableUnavailableUnavailableUnavailable
Gross margin64.2%63.6%UnavailableUnavailable65.0%67.1%UnavailableUnavailableUnavailableUnavailable
Operating margin6.0%0.1%7.2%-0.3%-68.8%-2.3%3.6%-2.0%-6.6%-17.9%
FCF margin18.6%-2.4%UnavailableUnavailable24.0%7.0%UnavailableUnavailableUnavailableUnavailable
SBC / revenue13.5%17.5%37.7%21.0%25.0%18.8%70.8%24.9%44.2%33.5%
Current ratio9.69x7.30x5.94x4.66x4.43x4.73x4.54x2.78x2.86x2.89x
Revenue YoY growth21.5%24.7%24.3%31.2%18.9%19.6%Unavailable-9.3%-32.6%-51.1%
Net margin158.4%4.3%58.9%2.2%-67.6%-2.0%82.5%-8.0%-105.1%-55.4%
R&D / revenue10.4%9.6%-0.4%9.7%8.4%6.5%-8.2%8.8%10.3%11.3%
CapEx / revenue3.7%0.6%UnavailableUnavailable7.4%0.8%UnavailableUnavailableUnavailableUnavailable
Long-term debt / equity0.00xUnavailable0.01x0.00xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate-1538.4%5.0%-5.1%11.7%Unavailable4.9%5.1%UnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BLFS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.